Log In
Print
BCIQ
Print
Print this Print this
 

Kogenate Bayer, Kogenate FS (BAY14-2222)

Also known as: Kogenate, antihemophilic factor

  Manage Alerts
Collapse Summary General Information
Company Bayer AG
DescriptionRecombinant Factor VIII (rFVIII) formulated with sucrose
Molecular Target Factor VIII
Mechanism of ActionProcoagulant
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsPrevent bleeding episodes and the risk of joint damage in patients with hemophilia A; Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A; Secondary prophylaxis of bleeding episodes and joint damage in patients with hemophilia A; Treat and prevent bleeding in patients with hemophilia A; Treat hemophilia A
Regulatory Designation U.S. - Undisclosed Review (Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults with hemophilia A)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today